Last reviewed · How we verify

DANYELZA — Competitive Intelligence Brief

DANYELZA (DANYELZA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GD2-targeting monoclonal antibody. Area: Oncology.

marketed GD2-targeting monoclonal antibody GD2 (disialoganglioside) Oncology Biologic Live · refreshed every 30 min

Target snapshot

DANYELZA (DANYELZA) — Memorial Sloan Kettering Cancer Center. DANYELZA is a monoclonal antibody that targets GD2, a glycolipid antigen expressed on neuroblastoma cells, enabling immune-mediated tumor cell destruction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DANYELZA TARGET DANYELZA Memorial Sloan Kettering Cancer Center marketed GD2-targeting monoclonal antibody GD2 (disialoganglioside)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GD2-targeting monoclonal antibody class)

  1. Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DANYELZA — Competitive Intelligence Brief. https://druglandscape.com/ci/danyelza. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: